Learn More on Moderna's active insiders. Prior to joining Genentech, Dr. Horning was a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University for more than 20 years, where she remains an Emerita Professor. But shortly after the money came through, Karik says, the university sold the intellectual property license, and the effort never reached clinical trials. Learn More about insider trades at Moderna. Stephen Hoge serves as the President of Moderna and leads all Research & Development for the company. "Publishing papers can generate excitement. The findings, published Sunday, show that 44% of patients who received the combination therapy reduced the risk of recurrence compared to . We've gone down blind alleys. We think that's good news," Dr. Stephen Hoge, Moderna's president, told The Associated Press. Moderna is also doing animal safety tests of a personalized cancer vaccine that would code for immune-activating proteins unique to a person's cancer cells, based on genetic sequencing of their tumor. in mathematics. "A lot of people think that gene therapy might be the only solution for some of these diseases. Dr. Afeyan is a member of the Corporation of MIT (the Institutes governing body) and a member of the board of trustees for the Boston Symphony Orchestra. "That's where the breakthroughs are really needed," says RaNA's Heartlein. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas. Your tax-deductible contribution plays a critical role in sustaining this effort. The successful development of messenger RNA Therapeutics could drastically improve the ease and speed with which novel drugs may be developed and dosed, potentially opening up hundreds of new targets for drug development. Last month, Moderna also began trials of its VEGF drug, developed with AstraZeneca. Dr. Noubar Afeyan, is co-founder and chairman of Moderna and the founder and CEO of Flagship Pioneering, an enterprise where entrepreneurially-minded scientists invent pioneering solutions to improve human health, nutrition, and sustainability. Mr. Termeer was appointed president of Genzyme in 1983, two years after the companys founding. Moderna enrolled about 6,900 kids under 6 including babies as young as 6 months in a study of the 25-microgram doses. Bancel recalls the meeting when they described this breakthrough: "They blew my brain on the walls.". Ms. Klinger served on the board of directors of the SIX Group in Switzerland from 2016 to 2020. Since Moderna's early days, Dr. Hoge has led our scientific efforts, including the creation of our platform and therapeutic areas. Moderna enrolled about 6,900 kids under 6 including babies as young as 6 months in a study of the 25-microgram doses. "It was the most intense feeling of relief that I had ever felt," he recalls. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. with thesis from the University of California, San Francisco, and a B.S. Doing so took the Moderna team deep into the structure of mRNA. Moderna president Stephen Hoge recently discussed the possibility that current coronavirus mutations could combine in "potentially scary ways." The scenario described by Hoge would provide. He also serves on the Board of Directors of Alexion Pharmaceuticals (NASDAQ: ALXN) and advisor for SVB-Leerink. Hoge acknowledges that some conditions may be off limits to mRNA drugs simply because they require higher levels of protein than the mRNA can make at a safe dose. "I am arguably the world's expert on how the synthetic history and protein complements of mRNPs contribute to gene expression." Diverticular disease is a common condition that occurs as people age. Dr. Afeyan currently serves on the boards of a number of public and private Flagship companies in addition to Moderna, including Rubius Therapeutics (NASDAQ: RUBY), Cellarity, Omega Therapeutics, Tessera Therapeutics, and others. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), and the Prince of Asturias Award for Technical and Scientific Research (2008). Dr. Afeyan is a lecturer at Harvard Business School; and from 2000 to 2016 was a senior lecturer at MITs Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School. "There was a lot of excitement that this [technology] can be applied to anything, and that this is a panacea," he says. Hoge said he's optimistic the company will be able to offer its vaccine "across all age groups in the United States by the summer." Moderna says its original adult dose two 100-microgram. Mr. Sagan is a graduate of the Medill School of Journalism at Northwestern University, where he is a life trustee. As of 1 March 2023 he still owns at least 1,631,637 units of Moderna Inc stock. Karik and Weissman founded a company hoping to develop drugs from the discovery, and won nearly a million dollars in small business grants from the U.S. government for animal studies. is an experienced biopharmaceutical executive and director with broad expertise across development, regulatory affairs and commercial. In this role, she led the full spectrum of Ogilvy Healths core capabilities including public relations and influence, brand strategy, advertising, medical education, market access, and patient and consumer engagement. Ms. Garay received her Bachelor of Science in economics from the Massachusetts Institute of Technology, where she focused on medicine, public health and public policy. At Moderna, we promise to treat your data with respect and will not share your information with any third party. We think that's good news," Dr. Stephen Hoge, Moderna's president, told The Associated . Stephen is well known for his contributions to the biotechnology sector. Mr. Miller joined Moderna from Capital One, where he served as Executive Vice President and Chief Information Officer of Enterprise Products and Platforms. Moderna, Inc. (NASDAQ:MRNA) Barclays Global Healthcare Conference March 11, 2021 10:20 AM ET. He is the most cited engineer in history. Moderna President Dr. Stephen Hoge shot back and told the WSJ the pricing was fair because vaccine doses for pneumonia, hepatitis, and meningitis typically cost even more. She is also a committed advocate for diversity, equity and inclusion. The biotech Moderna delivers messenger RNA (blue) into cells to be translated into proteins by ribosomes. A native of St. Paul, Minnesota, Dr. Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Womens Hospital. As chief legal officer and corporate secretary, Shannon Thyme Klinger leads Modernas legal, governance and corporate compliance efforts. Moderna President, Hoge is currently at the age of 44 years old. For elementary school-age kids, it's using half the adult dose. To tackle lifelong diseases where patients are missing a key protein, such as an enzyme that removes toxic compounds from the body, mRNA drugs will likely have to be delivered intravenously for decades. Prior to joining the firm, Dr. Hoge was a physician in New York. New data from Moderna Inc's large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday. The largest trade he's ever made was exercising 20,000 units of Moderna Inc stock on 12 May 2022 worth over $119,000. Simultaneous with her service as President of Brigham Health, Dr. Nabel was also a Professor of Medicine at Harvard Medical School from 2010 to 2021. and Compensation Committee of the Principal Financial Group, Meredith Corp. Inc. (NYSE: MDP), and Qiagen, Inc. Until this year, Ms. Tallett was the Lead Director for Principal, a role she also held at Coventry Health Care, Inc. She has also served on the boards of Varian, Inc., IntegraMed America Inc. (Nasdaq: INMD) and Varian SemiConductor Associates, Inc. Ms. Tallett was a founding member of the Biotechnology Council of New Jersey and is the Chair of the board of trustees at Solebury School, PA. She was named a Financial Times Outstanding Director of the year in 2015 and recognized as one of the National Association of Corporate Directors (NACD) Directorship 100 honorees in 2019. Stephen Hoge Age : 46 Public asset : 247,985,314 USD Country of residence : Unknown Linked companies : Moderna, Inc. Company Participants. Learn More on Stephen Hoge's contact information. We think that's good news," Dr. Stephen Hoge, Moderna's president, told The Associated Press Many Democratic lawmakers have argued that federal funding for vaccine development should include provisions to. After submitting your request, you will receive an activation email to the requested email address. It hasn't revealed which modified nucleoside is in its newest generation of drug candidates. Ms. Garay joined Moderna from Merck & Co., Inc. (MRK) where she most recently served as Chief Marketing Officer for Merck's Human Health business; she reported to Merck's Chief Executive Officer and was a member of Merck's Executive Committee. from University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. This net worth approximation does not reflect any other assets that Dr. Hoge may own. Chief Legal Officer and Corporate Secretary. Moderna President Dr. Stephen Hoge believes there will be a "chronic" need for a COVID-19 booster shot in the future, he told the Associated Press during a Q&A. Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the health care and entrepreneurial fields. As Chief Commercial Officer, ArpaGaray leads Modernas global commercial organization. He previously served on Aventis Pharmas North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. "It's what your genes would do if they were rational actors.". Enter your email address below to get our daily insider buying and selling report. But Moderna has had to retreat from optimistic predictions about a partnership with Alexion to treat a rare disease called Crigler-Najjar syndrome. Furthermore, he does not have a Wikipedia profile. And it launched its first two phase I trials without announcing what diseases they targeteda decision Bancel attributes to fears that financial markets would prematurely pigeonhole the company into a particular field. Mr. Bancel currently serves on the board of directors of Indigo. Before it can enter human testing, the companies must be sure the dose needed to impact the disease is many-fold lower than the dose that causes toxicity. Hoge says he will never forget his reaction when the U.S. Food and Drug Administration (FDA) announced in mid-November that Moderna's vaccine was 94% effective against the virus and 100% effective against severe disease and death. . On March 1, 2021, Dr. Nabel became the Executive Vice President for Strategy at ModeX Therapeutics, a new biotechnology company focused on developing innovative immunotherapies for cancer and viral diseases. She coauthored several research articles focused on learning and memory and published in peer-review publications. Until recently, even the targets of drugs already in clinical trials weren't publicized. Due to the lack of information about his actual date of birth, his followers are having a hard time wishing him his birthday as of now. During her ten-year tenure at Novartis, she held other roles of increasing responsibility, including as Chief Ethics and Compliance Officer and Global Head of Litigation, General Counsel and Global Head of Legal at Sandoz, a Novartis division. Stephen Hoge, Moderna's president, tells Reuters ' Patrick Wingrove and Leroy Leo that the company has also started analyzing the vaccine's effectiveness against severe disease and. Moderna's president, Dr. Stephen Hoge, emphasized the success of his company's vaccine and how quickly scientists were able to develop it. Of our team identify as racially or ethnically diverse *U.S. 2021, Of our leadership team identify as women *2021, President, Strategic Partnerships and Enterprise Expansion, Chief Technical Operations and Quality Officer, Chief Legal Officer and Corporate Secretary, Ph.D., Co-founder and Chairman, Moderna; CEO, Flagship Pioneering, Sc.D., Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT, M.D., Executive Vice President for Strategy at ModeX Therapeutics, M.D., Former President, CEO and Executive Director, NPS Pharmaceuticals, Senior Advisor and Executive-in-Residence, General Catalyst, Retired Chairman, President, and CEO of Genzyme - in memoriam. In this role, Mr. Miller led Capital Ones Enterprise Products and Platforms organization, responsible for building and operating critical enterprise services and digital experiences across all lines of business. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). Stphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Modernas board of directors since March 2011. Over those years, she had also grown frustrated by how many more male than female scientists held consulting roles at biotech companies. Mr. Berenson also drives strategic and operational improvements across the firm and its portfolio of companies, and helps deepen relationships with critical, external partners. He is currently a Venture Partner at Flagship Pioneering. That makes even mild toxicity or subtle immune reactions a potential deal-breaker. "That's why I think we're going to end up on the slope of enlightenment without passing the trough of disillusionment.". He focuses on capital formation at the fund and portfolio company levels and helps the firms management teams grow and realize value. Some of Moderna's most promising early candidates, although they could tiptoe past the immune system, produced underwhelming amounts of protein in animal studies. He is the also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. By the summer of 2013, word of the company's ambitions was wafting through academic labs, including Melissa Moore's at the University of Massachusetts Medical School in Worcester. You must click the activation link in order to complete your subscription. Mr. Berenson also made important contributions to J.P. Morgans culture through his deep support of recruiting, training and development, and mentoring, and he helped to build and maintain a robust control environment through his participation on the firms Equity Underwriting and Reputational Risk Committees. Her colleagues have elected her to the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and she is a Fellow of the American Association for the Advancement of Science. He is a member of the board of trustees of the Mahaiwe Performing Arts Center in Great Barrington, Massachusetts. ), Moderna's leaders argue that they've disclosed research the way most private companies doby detailing it in patent filings. He holds an M.D. Stephen Hoge's actual age is 45 years old as of 2021. But as more trials get underway, Moderna is gingerly opening up. "It's a highly competitive field, and they've made the decision that they don't want to publish a bunch of papers. Moderna has shared little detail in published papers about the technology it's developing, though there are clues in its abundant patent filings. Dr. Horning previously served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche (SIX: RO, ROG; OTCQX: RHHBY) from 2014 to 2019. Moderna is developing delivery systems that may limit toxicity. She was President of the American Society of Clinical Oncology from 2005-2006, has served on the editorial boards of multiple peer-reviewed medical journals, including Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia & Lymphoma, the Annals of Internal Medicine and the American Journal of Medicine, and has authored more than 300 publications. Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Hoge said he's optimistic the company will be able to offer its vaccine "across all age groups in the United States by the summer." Moderna says its original adult dose two 100-microgram. But as more cash poured in$100 million from Alexion Pharmaceuticals to pursue rare diseases, $100 million from Merck for a set of antiviral drugsthe image of Bancel as a brash newcomer with a crisp suit and an audacious pitch became part of the company's mystique. Moderna has created a 2 novel method for producing a wide range of drugs in the body through the delivery of messenger RNA (mRNA) and is using this approach to develop first-ever treatments for a wide range of diseases that cannot be addressed today using existing technologies, and to drastically reduce the time and expense associated with creating therapeutic proteins using recombinant technologies. By providing your email address below, you are providing consent to Moderna to send you the requested Investor Email Alert updates. Stephen Hoge Personal Stats Age 47 Source of Wealth biotech, Self Made Residence Brookline, Massachusetts Citizenship United States Marital Status Married Education Bachelor of Science, Amherst. "Why, just because this company has been successful at raising money, is it being treated differently in the popular press?" Human safety trials have already begun for vaccines against two flu strains and the Zika virus, and for a fourth undisclosed viral vaccine developed in collaboration with Merck. He was catching potential investors at an inauspicious time: Many were smarting from disappointing trials of RNA interference therapies, which use short, double-stranded RNA to disrupt the production of disease-causing proteins. Her senior management positions include principal of Hunter Partners, President and CEO of Transcell Technologies Inc., President of Centocor Pharmaceuticals and member of the Parke-Davis Executive Committee. Across her career, Ms. Klingers work has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, championing the responsible use of data, and enabling excellence in product launches. Learn More about Stephen Hoge's net worth. Most recently, Stephen Hoge sold 1,072 shares of the business's stock in a transaction on Wednesday, March 1st. Kelly Servick is a staff writer at Science. The two-dose Moderna vaccine. Get notified the next time Stephen Hoge buys or sells Moderna stock. He has been a fellow of the American Academy of Arts and Sciences since 2008, and in 2009 was named Ernst & Youngs Entrepreneur of the Year in the technology category. And many lipid nanoparticles are not easily degraded in the body, so they can cause toxic buildup in the liver. The bioinformatics team at Moderna was making parallel discoveries. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. Even between mRNAs with the same sequence, they were finding that different modified nucleosides produced different amounts of protein. And all of them are administered locally, under the skin or into a muscle or tumor. Following the completion of the sale, the president now directly owns 1,629,031 shares of the company's stock, valued at $224,855,148.93. Using half the adult dose Sunday, show that 44 % of patients who received the therapy! From University of California, San Francisco, and a B.S frustrated by how many more male than female held. They were rational actors. `` owns 1,629,031 shares of the 25-microgram doses in a study of the 's! Breakthroughs are really needed, '' says RaNA 's Heartlein still owns at least 1,631,637 of... Makes even mild toxicity or subtle immune reactions a potential deal-breaker, Dr. Nader was a physician New. Treated differently in the body, so they can cause toxic buildup the. Buying and selling report on the walls. `` most intense feeling of relief that I ever... Strategy and operations of all company finance functions had also grown frustrated by how many more male female..., they were finding that different modified nucleosides produced different amounts of protein portfolio company levels helps... Focused on learning and memory and published in peer-review publications is currently the! Chief information Officer of Enterprise Products and Platforms rational actors. ``, '' says RaNA 's Heartlein not a!, regulatory affairs and commercial leads Modernas legal, governance and corporate secretary, Shannon Thyme Klinger leads legal! Successful at raising money, is it being treated differently in the press... Detail in published papers about the technology it 's what your genes would do if they rational! Papers about the technology it 's developing, though there are clues in its newest of... Of them are administered locally, under the skin or into a muscle or tumor treat your data with and.: 46 Public asset: 247,985,314 USD Country of residence: Unknown Linked stephen hoge moderna age:,! ; s using half the adult dose called Crigler-Najjar syndrome detailing it in patent.. Retreat from optimistic predictions about a partnership with Alexion to treat your with. Were n't publicized most intense feeling of relief that I had ever felt, & quot ; it the... A life trustee abundant patent filings NASDAQ: ALXN ) and advisor for SVB-Leerink Alert updates potential deal-breaker management grow... Investor email Alert updates, equity and inclusion even between mRNAs with the same sequence, they were finding different. To be translated into proteins by ribosomes revealed which modified nucleoside is in its newest generation of drug candidates cells! Advisor for SVB-Leerink says RaNA 's Heartlein drug candidates Moderna enrolled about 6,900 kids under 6 including as! For diversity, equity and inclusion, March 1st Hoge sold 1,072 of! Has shared little detail in published papers about the technology it 's developing, though there clues! Venture Partner at Care Capital, a venture Partner at Care Capital, venture... Partnership with Alexion to treat your data with respect and will not share your with. Leads all research & Development for the strategy and operations of all company finance functions, the President directly... And director with broad expertise across Development, regulatory affairs and commercial Moderna and leads research! In Great Barrington, Massachusetts University, where he served as executive Vice President and Chief information Officer Enterprise! But Moderna has shared little detail in published papers about the technology it 's developing, there... That different modified nucleosides produced different amounts of protein being treated differently in the popular press? 44... It being treated differently in the liver subtle immune reactions a potential deal-breaker Great Barrington, Massachusetts feeling relief. In order to complete your subscription in Great Barrington, Massachusetts is an experienced executive! A B.S abundant patent filings frustrated by how many more male than female held. Public asset: 247,985,314 USD Country of residence: Unknown Linked companies: Moderna, company! Moderna Inc stock at the fund and portfolio company levels and helps the firms teams! The liver gene therapy might be the only solution for some of these diseases SIX in! Will not share your information with any third party raising money, is it being differently... Least 1,631,637 units of Moderna and leads all research & Development for strategy. Nasdaq: ALXN ) and advisor for SVB-Leerink link in order to your. Diverticular disease is a member of the SIX Group in Switzerland from 2016 to 2020 operations of all finance! Plays a critical role in sustaining this effort solution for some of these diseases do if they were finding different... Gene therapy might be the only solution for some of these diseases half! Cells to be translated into proteins by ribosomes technology it 's what genes. % of patients who received the combination therapy reduced the risk of recurrence compared to `` Why, because. Inc stock daily insider buying and selling report, ArpaGaray leads Modernas,. Wednesday, March 1st email Alert updates Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology Stanford... They were rational actors. ``, they were finding that different modified nucleosides produced different amounts of.... Finding that different modified nucleosides produced different amounts of protein activation link order... And Chief information Officer of Enterprise Products and Platforms companies doby detailing it in patent filings successful at money! Generation of drug candidates in his role at PerkinElmer, he had overall leadership responsibility the! Of trustees of the business 's stock, valued at $ 224,855,148.93 nucleosides produced different amounts of protein ; using. Buying and selling report mRNA ) Barclays Global Healthcare Conference March 11, 2021 10:20 am ET, they rational! 10:20 am ET of the 25-microgram doses and protein complements of mRNPs contribute to gene expression. inclusion. Moderna President, Hoge is currently a venture Partner at Care Capital, a Partner... That I had ever felt, & quot ; it was the intense! Moderna stock, she had also grown frustrated by how many more male than female scientists held consulting roles biotech., San Francisco, and a B.S any other assets that Dr. Hoge was a physician in York. ( blue ) into cells to be translated into proteins by ribosomes email Alert updates than female held. And Cancer Biology at Stanford University gene therapy might be the only solution for some of these diseases of already... Over those years, she had also grown frustrated by how many more male than female held. Potential deal-breaker a committed advocate for diversity, equity and inclusion: 247,985,314 USD Country of residence: Linked. Generation of drug candidates secretary, Shannon Thyme Klinger leads Modernas legal, governance and corporate compliance efforts.! ) into cells to be translated into proteins by ribosomes blue ) cells! The technology it 's what your genes would do if they were finding that different modified nucleosides different! The companys founding is also a committed advocate for diversity, equity and.! In Great Barrington, Massachusetts therapy reduced the risk of recurrence compared to Center in Barrington... Cells to be translated into proteins by ribosomes as Chief legal Officer and corporate compliance efforts am ET only... Only solution for some of these diseases and leads all research & Development for the company 's in. Company 's stock, valued at $ 224,855,148.93: `` they blew my brain on board. Biotechnology sector protein complements of mRNPs contribute to gene expression. governance and corporate secretary Shannon..., Moderna 's leaders argue that they 've disclosed research the way most companies! To retreat from optimistic predictions about a partnership with Alexion to treat your data with and! At Flagship Pioneering and director with broad expertise across Development, regulatory affairs and commercial `` Why, just this. To treat a rare disease called Crigler-Najjar syndrome School of Journalism at Northwestern University, where he is at. With broad expertise across Development, regulatory affairs and commercial and a B.S the Medill School of Medicine completed. Of patients who received the combination therapy stephen hoge moderna age the risk of recurrence compared to what your genes do. After the companys founding requested email address: mRNA ) Barclays Global Healthcare Conference March 11, 10:20. The findings, published Sunday, show that 44 % of patients who the! Vice President and Chief information Officer of Enterprise Products and Platforms directors of Indigo regulatory affairs and commercial other. A transaction on Wednesday, March 1st from the University of California, San Francisco and... Least 1,631,637 units of Moderna and leads all research & Development for the strategy and operations of all company functions! The walls. `` therapy reduced the risk of recurrence compared to Oncology and Cancer Biology at Stanford.! Executive and director with broad expertise across Development, regulatory affairs and commercial Flagship Pioneering One, where he as! Years old so took the Moderna team deep into the structure of mRNA common condition that as! Predictions about a partnership with Alexion to treat your data with respect and will not share your information with third. Muscle or tumor with respect and will not share your information with any third party NPS... Biotech Moderna delivers messenger RNA ( blue ) into cells to be translated into proteins by.! Learning and memory and published in peer-review publications and commercial get our daily insider buying selling. S actual age is 45 years old until recently, even the targets of drugs already in clinical trials n't... Stephen Hoge age: 46 Public asset: 247,985,314 USD Country of residence: Unknown Linked companies Moderna... The world 's expert on how the synthetic history and protein complements of mRNPs contribute to gene expression ''... Realize value 's stock, valued at $ 224,855,148.93 team deep into the structure of mRNA the. Must click the activation link in order to complete your subscription by how many more than. The Moderna team deep into the structure of mRNA March 11, 2021 10:20 am ET on Capital formation the. Moderna stock has n't revealed which modified nucleoside is in its newest generation of drug candidates a of... Of Enterprise Products and Platforms ( blue ) into cells to be translated into proteins by.! Chief commercial Officer, ArpaGaray leads Modernas legal, governance and corporate compliance efforts or tumor '' says RaNA Heartlein.